NCT00002043View on ClinicalTrials.gov

Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC)

NACompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
Pneumonia, Pneumocystis CariniiHIV Infections
Interventions
DRUG

Dapsone

Trial Locations (1)

90095

UCLA CARE Ctr, Los Angeles

Sponsors
All Listed Sponsors
lead

Jacobus Pharmaceutical

INDUSTRY

NCT00002043 - Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC) | Biotech Hunter | Biotech Hunter